This morning, positive results from a phase 2a study testing an experimental asthma drug developed by biotech Regeneron (NASDAQ:REGN) and big pharma company Sanofi (NASDAQ:SNY) were published in the New England Journal of Medicine. In the following video, health-care analyst Max Macaluso discusses the details of the trial and offers his long-term view on both stocks.